ArticleMedical hypotheses2020
Should an intersection between visceral leishmaniasis endemicity and the COVID-19 pandemic be considered?
Article in Medical hypotheses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 26 citations in OpenAlex.
- Emergence of coinfection with visceral Leishmania infantum in COVID-19 patients: a case‒control field study in an endemic area of visceral leishmaniasis in Iran.BMC infectious diseases · 2024Article
- The Impact of COVID-19 Pandemic on Arthropod-Related Diseases.Journal of arthropod-borne diseases · 2023Review
- Third Case of Visceral Leishmaniasis in COVID-19: Mini Review Article.Pathogens (Basel, Switzerland) · 2022Review
- Severe visceral leishmaniasis and COVID-19 coinfection in an immunosuppressed patient.Revista do Instituto de Medicina Tropical de Sao Paulo · 2022Article
- Climate Change and Environmental Influence on Prevalence of Visceral Leishmaniasis in West Pokot County, Kenya.Journal of tropical medicine · 2022Article
- Nutritional Modulation of the Immune Response Mediated by Nucleotides in Canine Leishmaniosis.Microorganisms · 2021Review
- The impact of COVID-19 on neglected parasitic diseases: what to expect?Trends in parasitology · 2021Article
- Vulnerabilities to and the Socioeconomic and Psychosocial Impacts of the Leishmaniases: A Review.Research and reports in tropical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic caused by the infection with the novel Coronavirus SARS-CoV-2, revealed individual and global vulnerabilities, in which we highlight the social, economic, and political aspects and the health systems' organization in the countries. Brazil remains with a high transmission rate and presents a centripetal distribution as observed through a more sustained growth in the number of municipalities affected, outlining a profile of invasion of poor communities. Several vulnerabilities overlap with precarious housing conditions, lack of basic sanitation, malnutrition, and endemicity for neglected chronic diseases such as visceral leishmaniasis (VL). COVID-19 and VL evidently do not share clinical features, but exactly because of the distinct immunopathogenesis between the diseases, patients with VL may present a vulnerability in the immune system against antiviral responses. Considering that VL susceptibility seems to be related to an inefficient and polarized immune response, it is likely that in endemic areas, the overlap of social weaknesses added to individual vulnerability by immune polarization may aggravate the COVID-19 condition. In this sense, we reinforce that possible relationships between endemic neglected diseases such as VL and pandemic SARS-CoV-2 infection need to be further considered and investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.